nach oben

Current Bladder Dysfunction Reports

Erschienen in:

14.08.2018 | Neurogenic Bladder (C Powell, Section Editor)

Safely Avoiding Surgery in Adult Neurogenic Bladder

verfasst von: Giulia I. Lane, Sean P. Elliott

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the literature regarding non-surgical management of adult patients with high-pressure neurogenic bladder.

Recent Findings

Established therapies that facilitate bladder storage and emptying include anticholinergic medications, intradetrusor onabotulinum toxin injection, and intermittent catheterization. Application of these strategies to patients with elevated detrusor leak point pressures has shown improvement in bladder compliance and preservation of renal function. New interventions in the algorithm of management of patients with poor bladder compliance, such as beta-3 agonists and sacral neuromodulation to facilitate bladder storage the use of alpha antagonists and intraurethral onabotulinum toxin to facilitate bladder emptying are developing.

Summary

A multimodal approach to adult patients with high-pressure neurogenic bladder which includes intermittent catheterization, pharmacologic therapy, and intravesical onabotulinumtoxin injection has been associated with improved bladder compliance and preservation of renal function. Augmentation cystoplasty may be reserved for refractory cases. Data is emerging regarding new interventions that can facilitate bladder storage and emptying.

Wein A, Dmochowski RR. Neuromuscular dysfunction of the lower urinary tract. In: Wein A, Kavoussi LR, Partin AW, Peters C, editors. Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016. p. 1793.

• Blok B, Pannek J, Castro Diaz D, del Popolo G, Groen J, Gross T et al. European Association of Urology Guidelines on Neuro-Urology. 2017. https://uroweb.org/guideline/neuro-urology/. Accessed 12 Dec 2017. Comprehensive and evidence-based guidance for urologists.

Nitti VW, Brucker BM. Urodynamic and video-urodynamic evaluation of the lower urinary tract. In: Wein A, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. Philadelphia: Elsevier; 2017. p. 1726.

Incontinence. 5th International Consultation on Incontinence. 5th ed. Paris: ICUD-EAU; 2013.

McGuire EJ. Urodynamics of the neurogenic bladder. Urol Clin N Am. 2010;37(4):507–16. https://doi.org/10.1016/j.ucl.2010.06.002. CrossRef

Shreck E, Gioia K, Lucioni A. Indications for augmentation cystoplasty in the era of onabotulinumtoxinA. Curr Urol Rep. 2016;17(4):27. https://doi.org/10.1007/s11934-016-0585-3. CrossRefPubMed

Creevy CD. The management of neurogenic vesical dysfunction. Am Pract Dig Treat. 1948;3(2):71–4.

Jameson RM. Surgical management of the neurogenic bladder and its complications. Br J Clin Pract. 1969;23(9):359–63.PubMed

Wein AJ, Raezer DM, Benson GS. Management of neurogenic bladder dysfunction in the adult. Urology. 1976;8(5):432–43.CrossRefPubMed

10.

Lapides J, Diokno AC, Silber SM, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 2002;167(4):1584–6. https://doi.org/10.1016/S0022-5347(05)65158-0.CrossRefPubMed

11.

McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205–9.CrossRefPubMed

12.

Dray EV, Cameron AP. Identifying patients with high-risk neurogenic bladder. Urol Clin. 44(3):441–52. https://doi.org/10.1016/j.ucl.2017.04.010.

13.

Ghoniem GM, Bloom DA, McGuire EJ, Stewart KL. Bladder compliance in meningomyelocele children. J Urol. 1989;141(6):1404–6.CrossRefPubMed

14.

McGuire EJ. Bladder compliance. J Urol. 1994;151(4):965–6.CrossRefPubMed

15.

National Spinal Cord Injury Statistical Center, Facts and Figures at a Glance. University of Birmingham, Birmigmham Alabama. 2017. https://www.nscisc.uab.edu/Public/Facts and Figures - 2017.pdf. Accessed Feb 13 2018.

16.

• Ginsberg D. Surveillance and management of urologic complications after spinal cord injury. In: Elliott SP, Gomez R, editors. Urologic management of the spinal cord injured patient. Montreal: Societe Internationale d'Urologie; 2016. p. 87–146. An international review of literature with evidence-based recommendations for clinical practice.

17.

Filler G, Lee M. Educational review: measurement of GFR in special populations. Pediatr Nephrol (Berlin, Germany). 2017; https://doi.org/10.1007/s00467-017-3852-8.

18.

Pham-Huy A, Leonard M, Lepage N, Halton J, Filler G. Measuring glomerular filtration rate with cystatin C and beta-trace protein in children with spina bifida. J Urol. 2003;169(6):2312–5. https://doi.org/10.1097/01.ju.0000060205.23406.13.CrossRefPubMed

19.

Dangle PP, Ayyash O, Kang A, Bates C, Fox J, Stephany H, et al. Cystatin C-calculated glomerular filtration rate—a marker of early renal dysfunction in patients with neuropathic bladder. Urology. 2017;100:213–7. https://doi.org/10.1016/j.urology.2016.08.011.CrossRefPubMed

20.

Winters JC, Dmochowski RR, Goldman HB, Herndon CD, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464–72. https://doi.org/10.1016/j.juro.2012.09.081. CrossRefPubMed

21.

Abrams P. Urodynamics. 3rd ed. London: Springer-Verlag; 2006.

22.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.CrossRefPubMed

23.

Lane GI, Gor RA, Katorski J, Elliott SP. Clinical outcomes of non-surgical management of detrusor leak point pressures above 40 cm water in adults with congenital neurogenic bladder. Neurourol Urodyn. 2018; https://doi.org/10.1002/nau.23535.

24.

Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182(3):1062–7. https://doi.org/10.1016/j.juro.2009.05.038.CrossRefPubMed

25.

Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104(9):1246–50. https://doi.org/10.1111/j.1464-410X.2009.08600.x.CrossRefPubMed

26.

Cameron AP. Non-surgical urologic management of neurogenic bladder after spinal cord injury. In: Elliott SP, Gomez R, editors. Urologic management of the spinal cord injured patient. Montreal: Societe Internationale d'Urologie; 2016. p. 147–204.

27.

• Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5(1):51–62. https://doi.org/10.3978/j.issn.2223-4683.2015.12.07. Comprehensive review of medical management of neurogenic bladder. PubMedPubMedCentralCrossRef

28.

Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective beta3-Adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–90. https://doi.org/10.1016/j.eururo.2017.12.022.CrossRefPubMed

29.

Krhut J, Borovicka V, Bilkova K, Sykora R, Mika D, Mokris J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018; https://doi.org/10.1002/nau.23566.

30.

Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. LUTS. 2018; https://doi.org/10.1111/luts.12218.

31.

Zachariou A, Filiponi M, Baltogiannis D, Giannakis J, Dimitriadis F, Tsounapi P, et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol. 2017;24(6):9107–13.PubMed

32.

Chen SF, Kuo HC. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Low Urin Tract Symptoms. 2018; https://doi.org/10.1111/luts.12215.

33.

Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82. https://doi.org/10.1038/sc.2015.195.CrossRefPubMed

34.

Baron M, Grise P, Cornu JN. How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? World J Nephrol. 2016;5(2):195–203. https://doi.org/10.5527/wjn.v5.i2.195.CrossRefPubMedPubMedCentral

35.

Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665. https://doi.org/10.1056/nejm200003023420918. CrossRefPubMed

36.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50. https://doi.org/10.1016/j.eururo.2011.07.002.CrossRefPubMed

37.

Ginsberg D, Gousse A, Keppenne V, Sievert K-D, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor Overactivity. J Urol. 2012;187(6):2131–9. https://doi.org/10.1016/j.juro.2012.01.125.CrossRefPubMed

38.

Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol. 2013;31(6):1469–74. https://doi.org/10.1007/s00345-012-0984-0.CrossRefPubMed

39.

Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. https://doi.org/10.1097/01.ju.0000162035.73977.1c.CrossRefPubMed

40.

Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35. https://doi.org/10.1016/j.juro.2011.02.004.CrossRefPubMed

41.

Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport(R) (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36(2):457–62. https://doi.org/10.1002/nau.22954.CrossRefPubMed

42.

• Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol. 2016;5(1):117–26. https://doi.org/10.3978/j.issn.2223-4683.2015.12.01. Contemporary review of literature regarding neuromodulation for neurogenic bladder. PubMedPubMedCentralCrossRef

43.

• Barboglio Romo PG, Gupta P. Peripheral and sacral neuromodulation in the treatment of neurogenic lower urinary tract dysfunction. Urol Clin. 44(3):453–61. https://doi.org/10.1016/j.ucl.2017.04.011. Up to date review of literature regarding neuromodulation for neurogenic bladder.

44.

Chartier-Kastler EJ, Denys P, Chancellor MB, Haertig A, Bussel B, Richard F. Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. Neurourol Urodyn. 2001;20(1):61–71.CrossRefPubMed

45.

Chaabane W, Guillotreau J, Castel-Lacanal E, Abu-Anz S, De Boissezon X, Malavaud B, et al. Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol Urodyn. 2011;30(4):547–50. https://doi.org/10.1002/nau.21009.CrossRefPubMed

46.

Wollner J, Krebs J, Pannek J. Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(2):137–40. https://doi.org/10.1038/sc.2015.124.CrossRefPubMed

47.

Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5. https://doi.org/10.1038/sc.2013.155.CrossRefPubMed

48.

de Seze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306–11. https://doi.org/10.1002/nau.20958.CrossRefPubMed

49.

Kabay S, Kabay SC, Yucel M, Ozden H, Yilmaz Z, Aras O, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964–8. https://doi.org/10.1002/nau.20733.CrossRefPubMed

50.

•• Wang HH, Lloyd JC, Wiener JS, Routh JC. Nationwide trends and variations in urological surgical interventions and renal outcome in patients with spina bifida. J Urol. 2016;195(4 Pt 2):1189–94. https://doi.org/10.1016/j.juro.2015.11.033. Temporal and geographic trends in urologic surgery in patients with spina bifida and their relationship to chronic renal insufficiency. CrossRefPubMedPubMedCentral

51.

Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012;109(9):1280–93. https://doi.org/10.1111/j.1464-410X.2011.10650.x.CrossRefPubMed

52.

• Jaggi A, Drake M, Siddiqui E, Fatoye F. A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines. Neurourol Urodyn. 2018; https://doi.org/10.1002/nau.23581. Comparison of NICE, EAU and ICI guidelines on neurogenic bladder.

53.

National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease. London: Royal College of Physicians (UK).National Clinical Guideline Centre.; 2012.

55.

Wang SC, McGuire EJ, Bloom DA. A bladder pressure management system for myelodysplasia—clinical outcome. J Urol. 1988;140(6):1499–502.CrossRefPubMed

56.

Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Libr. 2013; https://doi.org/10.1002/14651858.CD004375.pub4.

57.

Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184(1):213–7. https://doi.org/10.1016/j.juro.2010.03.008.CrossRefPubMed

58.

Lane GI, Downs TM, Soubra A, Rao A, Hemsley L, Laylan C, et al. Tolerability of repeat use of blue light cystoscopy with Hexaminolevulinate for patients with urothelial cell carcinoma. J Urol. 2017;197(3 Pt 1):596–601. https://doi.org/10.1016/j.juro.2016.09.076. CrossRefPubMed

59.

Levy ME, Elliott SP. Reconstructive techniques for creation of catheterizable channels: tunneled and nipple valve channels. Transl Androl Urol. 2016;5(1):136–44. https://doi.org/10.3978/j.issn.2223-4683.2016.01.04. PubMedPubMedCentralCrossRef

60.

Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–9.CrossRefPubMed

61.

Mehta S, Hill D, Foley N, Hsieh J, Ethans K, Potter P, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93(4):597–603. https://doi.org/10.1016/j.apmr.2011.11.020.CrossRefPubMed

62.

Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev. 2014(5):Cd004927. https://doi.org/10.1002/14651858.CD004927.pub4.

63.

Goldfarb RA, Pisansky A, Fleck J, Hoversten P, Cotter KJ, Katorski J, et al. Neurogenic lower urinary tract dysfunction in adults with cerebral palsy: outcomes following a conservative management approach. J Urol. 2016;195(4 Pt 1):1009–13. https://doi.org/10.1016/j.juro.2015.10.085. CrossRefPubMed

64.

Pakula AT, Van Naarden Braun K, Yeargin-Allsopp M. Cerebral palsy: classification and epidemiology. Phys Med Rehabil Clin N Am. 20(3):425–52. https://doi.org/10.1016/j.pmr.2009.06.001.

65.

Wecht JM, Bauman WA. Decentralized cardiovascular autonomic control and cognitive deficits in persons with spinal cord injury. J Spinal Cord Med. 2013;36(2):74–81. https://doi.org/10.1179/2045772312y.0000000056.CrossRefPubMedPubMedCentral

66.

Stubberud J, Langenbahn D, Levine B, Stanghelle J, Schanke AK. Emotional health and coping in spina bifida after goal management training: a randomized controlled trial. Rehabil Psychol. 2015;60(1):1–16. https://doi.org/10.1037/rep0000018.CrossRefPubMed

67.

Pruitt DW, Tsai T. Common medical comorbidities associated with cerebral palsy. Phys Med Rehabil Clin N Am. 20(3):453–67. https://doi.org/10.1016/j.pmr.2009.06.002.

68.

Lopes MA, Lima ED. Continuous use of intermittent bladder catheterization—can social support contribute? Rev Lat Am Enfermagem. 2014;22(3):461–6.CrossRefPubMedPubMedCentral

69.

Serres C. Shortage of home health workers forcing young Minneostans with disabilities into institutions. Star Trib. 2018;5:2018.

70.

DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23(2):207–18. https://doi.org/10.1037/0278-6133.23.2.207. CrossRefPubMed

71.

Krause JS, Carter RE. Risk of mortality after spinal cord injury: relationship with social support, education, and income. Spinal Cord. 2009;47(8):592–6. https://doi.org/10.1038/sc.2009.15.CrossRefPubMedPubMedCentral

72.

Muller R, Peter C, Cieza A, Geyh S. The role of social support and social skills in people with spinal cord injury—a systematic review of the literature. Spinal Cord. 2012;50(2):94–106. https://doi.org/10.1038/sc.2011.116. CrossRefPubMed

Titel: Safely Avoiding Surgery in Adult Neurogenic Bladder
verfasst von: Giulia I. Lane
Sean P. Elliott
Publikationsdatum: 14.08.2018
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 3/2018
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-018-0479-y

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Safely Avoiding Surgery in Adult Neurogenic Bladder

Abstract

Purpose

Recent Findings

Summary

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Cost-Effectiveness of Third-Line Therapies for Overactive Bladder

The Role of Chemical Sphincterotomy with Urethral Botulinum Toxin Injection in Patients with Neurogenic and Non-neurogenic Failure to Empty

New Concepts in Bladder Sensation and Urinary Urgency

Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory Urgency Urinary Incontinence)?

AUA Guidelines on Stress Urinary Incontinence: What Is New in the Guidelines?

Managing of Lower Urinary Tract Dysfunction Following Stroke

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie